Why the study?
Arrhythmogenic cardiomyopathy lacks etiological therapies, and the hypothesis that its causative mechanism involves defects in cardiac Ca2+ handling machinery requires discussion.
Answers are grounded in this paper and cite their sources.
Defects in the cardiac calcium handling machinery may be a central pathogenetic mechanism in arrhythmogenic cardiomyopathy, offering a potential therapeutic target.
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease characterized by sudden death in young people and featured by fibro-adipose myocardium replacement, malignant arrhythmias, and heart failure. To date, no etiological therapies are available. Mutations in desmosomal genes cause abnormal mechanical coupling, trigger pro-apoptotic signaling pathways, and induce fibro-adipose replacement. Here, we discuss the hypothesis that the ACM causative mechanism involves a defect in the expression and/or activity of the cardiac Ca2+ handling machinery, focusing on the available data supporting this hypothesis. The Ca2+ toolkit is heavily remodeled in cardiomyocytes derived from a mouse model of ACM defective of the desmosomal protein plakophilin-2. Furthermore, ACM-related mutations were found in genes encoding for proteins involved in excitation‒contraction coupling, e.g., type 2 ryanodine receptor and phospholamban. As a consequence, the sarcoplasmic reticulum becomes more eager to release Ca2+, thereby inducing delayed afterdepolarizations and impairing cardiac contractility. These data are supported by preliminary observations from patient induced pluripotent stem-cell-derived cardiomyocytes. Assessing the involvement of Ca2+ signaling in the pathogenesis of ACM could be beneficial in the treatment of this life-threatening disease.
No takes yet. Share an insight, caveat, or question.
Moccia et al. (2019) conducted a review in Arrhythmogenic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: